10 studies found for:    snx5422
Show Display Options
Rank Status Study
1 Active, not recruiting Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma
Condition: Cancer
Intervention: Drug: SNX-5422
2 Recruiting Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers
Condition: Cancer
Intervention: Drug: SNX-5422
3 Recruiting Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
Condition: Cancer
Intervention: Drug: SNX-5422
4 Completed SNX-5422 to Treat Solid Tumor Cancers and Lymphomas
Conditions: Lymphoma;   Neoplasms
Intervention: Drug: SNX-5422
5 Recruiting Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors
Condition: Cancer
Intervention: Drug: SNX-5422
6 Recruiting Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
Condition: Cancer
Intervention: Drug: SNX-5422
7 Completed Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
Condition: Cancer
Intervention: Drug: SNX-5422
8 Completed Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas
Conditions: Solid Tumor Malignancy;   Lymphoid Malignancy (Lymphoma and CLL);   Leukemia;   Lymphoma
Intervention: Drug: SNX-5422 Mesylate Hsp90 inhibitor
9 Completed Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
Condition: Hematologic Neoplasms
Intervention: Drug: SNX-5422
10 Completed Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies
Condition: Cancer
Intervention: Drug: SNX-5422

Indicates status has not been verified in more than two years